These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2246 related articles for article (PubMed ID: 34145792)

  • 1. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The update of chimeric antigen receptor-T cells therapy in glioblastoma.
    Chou CJ; Lin CF; Chen YW; Huang PI; Yang YP; Wang ML; Hung KF; Lee YY
    J Chin Med Assoc; 2020 May; 83(5):442-445. PubMed ID: 32217989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.
    Sengupta S; Mao G; Gokaslan ZS; Sampath P
    Cancer Gene Ther; 2017 Mar; 24(3):121-129. PubMed ID: 27767090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment.
    Feldman L; Brown C; Badie B
    Neurosurgery; 2021 May; 88(6):1056-1064. PubMed ID: 33575786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.
    Agosti E; Garaba A; Antonietti S; Ius T; Fontanella MM; Zeppieri M; Panciani PP
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
    Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
    Front Immunol; 2020; 11():594271. PubMed ID: 33224149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
    Yoo HJ; Harapan BN
    Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
    Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
    Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma.
    Agliardi G; Liuzzi AR; Hotblack A; De Feo D; Núñez N; Stowe CL; Friebel E; Nannini F; Rindlisbacher L; Roberts TA; Ramasawmy R; Williams IP; Siow BM; Lythgoe MF; Kalber TL; Quezada SA; Pule MA; Tugues S; Straathof K; Becher B
    Nat Commun; 2021 Jan; 12(1):444. PubMed ID: 33469002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment.
    Kong D; Kwon D; Moon B; Kim DH; Kim MJ; Choi J; Kang KS
    Biomed Pharmacother; 2024 May; 174():116436. PubMed ID: 38508081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
    Zhou S; Sun H; Choi SI; Yin J
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?
    Prinzing BL; Gottschalk SM; Krenciute G
    Expert Rev Anticancer Ther; 2018 May; 18(5):451-461. PubMed ID: 29533108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.
    Montoya M; Gallus M; Phyu S; Haegelin J; de Groot J; Okada H
    Cells; 2024 Apr; 13(9):. PubMed ID: 38727262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
    Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H
    Front Immunol; 2018; 9():3062. PubMed ID: 30740109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages.
    Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C
    ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
    Salinas RD; Durgin JS; O'Rourke DM
    CNS Drugs; 2020 Feb; 34(2):127-145. PubMed ID: 31916100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments.
    Soler DC; Kerstetter-Fogle A; McCormick TS; Sloan AE
    J Neurooncol; 2022 Jan; 156(1):81-96. PubMed ID: 34825292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
    Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
    Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
    EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 113.